Envista (NYSE:NVST) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Key Points

• Envista reported quarterly EPS of $0.40, beating estimates by $0.04, while revenue of $691.5 million also topped expectations and grew 3.2% year over year.
• Core sales grew 2.7%, adjusted EBITDA rose 9%, and adjusted EPS increased 25%; the company raised its 2026 outlook to 3.75%–4.25% core sales growth and adjusted EPS of $1.54–$1.58.
• China sales declined at a low-double-digit rate amid orthodontics customer destocking ahead of VBP, which is expected to bring significant price cuts and pressure margins, though management anticipates volume and market-share gains.

Envista (NYSE:NVST - Get Free Report) issued its earnings results on Wednesday. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.36 by $0.04, FiscalAI reports. Envista had a net margin of 3.33% and a return on equity of 7.88%. The company had revenue of $691.50 million for the quarter, compared to analyst estimates of $688.74 million. During the same period in the previous year, the firm earned $0.32 EPS. The business's revenue was up 3.2% on a year-over-year basis.

Here are the key takeaways from Envista's conference call:

• Envista reported 2.7% core sales growth, with adjusted EBITDA up 9% and adjusted EPS up 25%; gross and EBITDA margins expanded 20 and 80 basis points, respectively. Free cash flow conversion was 97%, and net leverage remained low at 0.6x.
• The company raised its 2026 outlook, now expecting 3.75%–4.25% core sales growth, 12.5%–14% adjusted EBITDA growth, and adjusted EPS of $1.54–$1.58. Management said the fourth-quarter outlook implies slightly negative core growth, partly reflecting four fewer selling days and continued macro uncertainty.
• China sales fell at a low-double-digit rate as orthodontics customers destocked ahead of VBP; management expects the process to bring substantial price reductions, including about 50% for orthodontics and 10%–15% for implants. It expects VBP to support volume and share gains, but acknowledged margin pressure in China.
• Spark grew at a high-single-digit rate, diagnostics and implants each grew mid-single digits, and Envista said it continued to gain share in diagnostics. Management highlighted a strong new-product pipeline and said broader commercialization of recent launches will be a key growth priority for 2027.

Envista Price Performance

NVST stock traded up $2.44 on Wednesday, reaching $27.21. The company had a trading volume of 6,113,924 shares, compared to its average volume of 3,135,394. Envista has a 1 year low of $18.77 and a 1 year high of $30.42. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.07 and a current ratio of 2.43. The company's fifty day moving average is $24.49 and its 200 day moving average is $25.74. The company has a market cap of $4.37 billion, a P/E ratio of 46.91, a PEG ratio of 1.26 and a beta of 0.94.

Analyst Ratings Changes

NVST has been the subject of several recent analyst reports. JPMorgan Chase & Co. upgraded shares of Envista from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $29.00 to $32.00 in a research note on Thursday, September 3rd. Deutsche Bank Aktiengesellschaft set a $32.00 target price on shares of Envista in a research report on Thursday, September 3rd. Morgan Stanley set a $23.00 target price on shares of Envista in a research report on Thursday, August 6th. Leerink Partners dropped their target price on shares of Envista from $35.00 to $32.00 and set an "outperform" rating for the company in a report on Wednesday, October 14th. Finally, Weiss Ratings upgraded shares of Envista from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, August 6th. Six equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $28.86.

Insiders Place Their Bets

In other Envista news, SVP Mischa Reis sold 8,000 shares of the firm's stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $27.50, for a total transaction of $220,000.00. Following the completion of the transaction, the senior vice president owned 27,321 shares of the company's stock, valued at approximately $751,327.50. This trade represents a 22.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.99% of the company's stock.

Envista Company Profile

Envista Holdings Corporation NYSE: NVST is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral health professionals.

Envista's portfolio includes dental implants, orthodontic systems, digital imaging and workflow solutions, dental consumables, treatment equipment and related technologies. Its brands include Nobel Biocare, Ormco, DEXIS and Kerr, which provide products and services spanning implant dentistry, orthodontics, diagnostic imaging, restorative care and general dental practice management.

Envista was established as an independent public company in 2019 following its separation from Danaher Corporation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.